Quarterly ResultAug 12, 2026, 08:52 AM
Dyadic Q2 Net Loss $(2.12)M; Revenue $0.96M
AI Summary
Dyadic International reported a net loss of $(2.12) million for the second quarter ended June 30, 2026, compared to a net loss of $(1.79) million in the prior year, with total revenue slightly decreasing by 0.6% to $961,138. The company highlighted accelerating commercialization momentum, including initial pilot sales for cultivated-meat applications and increased productivity for recombinant human transferrin. Despite a decrease in cash position and increased operating loss, Dyadic emphasized strategic partnerships and advancements in its C1 biomanufacturing platform.
Key Highlights
- Net loss for Q2 2026 increased to $(2.12) million from $(1.79) million year-over-year.
- Total revenue for Q2 2026 was $961,138, a slight decrease of 0.6% from Q2 2025.
- Cash, cash equivalents, and investment securities decreased to $4.79 million as of June 30, 2026.
- Research and development expenses decreased by 47.2% to $332,621 in Q2 2026.
- General and administrative expenses increased by 17.6% to $1.69 million in Q2 2026.
- Achieved initial pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.
- Increased recombinant human transferrin productivity by approximately 80% through process improvements.
- Advanced Gates Foundation-funded RSV and malaria monoclonal antibody programs.
Price Impact
More from DYAI